These findings strongly suggest that IGF2BP2 regulates mRNA translation through m6A methylation, highlighting a novel oncogenic mechanism mediated by IGF2BP2 and positioning it as a potential therapeutic target in cancer. This evidence concerns the gene IGF2BP2 and cancer.